Estimating Heritability of Glycaemic Response to Metformin using Nationwide Electronic Health Records andPopulation-Sized Pedigree

Iris Kalka, Amir Gavrieli, Smadar Shilo, Hagai Rossman, Nitzan Shalom Artzi, Eran SegalResearch Square 2021 · DOI

Abstract

Variability of response to medication is a well-known phenomenon determined by both environmental and genetic factors. Understanding the heritable component of drug response is challenging due to small study cohorts and computational limitations. This study leverages 17 years of electronic health records (EHR) from Israel’s largest healthcare provider, encompassing over five million patients. By constructing a six-generation population-size pedigree and applying a Linear Mixed Model-based framework, we estimated the heritability ($h^2$) of glycated hemoglobin (HbA1c%) reduction after metformin treatment. We found heritability measures of 15.9% (95% CI, 1.2%–30.5%) in males and 20.9% (95% CI, 7.5%–34.3%) in females. This work demonstrates that while metformin response has a heritable component, the majority of variation is likely due to other factors, further motivating non-genetic analyses aimed at unraveling metformin’s mechanism of action.

Introduction

Metformin is the gold-standard first-line treatment for Type 2 Diabetes (T2D), yet clinical response varies significantly among patients. Quantifying the heritable component of this variation is crucial for personalized medicine but has traditionally required expensive genome-wide association studies (GWAS) or twin studies, which are often limited by sample size and the difficulty of separating genetic effects from shared environmental factors. This study investigates whether "real-world" data—specifically EHRs combined with national genealogical records—can provide a high-powered, low-cost alternative for estimating heritability.

Methods

Data Source and Cohort Selection

The study utilized the Clalit Health Services database in Israel, covering over five million people. From an initial pool of 721,123 T2D patients, a final cohort of 74,871 patients was selected. These patients met strict criteria, including no prior anti-diabetic medication, sufficient HbA1c measurements, and valid renal function. The dataset included over 1.3 million HbA1c measurements and 323,260 metformin prescriptions.

Pedigree-Based Heritability Estimation

Instead of direct DNA sequencing, the researchers constructed a six-generation population-sized pedigree using national registries. They used the Nadiv R package to calculate an Additive Relationship Matrix (ARM), which estimates the probability of shared alleles based on family relationships. To handle the computational burden of this massive pedigree, the team employed the Sci-LMM framework, which utilizes sparse Cholesky factorization to fit models in hours rather than days.

Phenotyping and Validation

The primary phenotype was the absolute reduction in HbA1c% following metformin initiation, adjusted for covariates like age, BMI, and dosage. As a "sanity check," the model was first used to estimate the heritability of adult height using 11.6 million measurements. Since height is a well-studied heritable trait, it served as a positive control to validate the pedigree-based approach.

Results

Validation via Height

The model estimated the heritability of height at 80.7%, which aligns perfectly with established literature. This result confirmed that the pedigree-based approach was robust enough to capture genetic signals from clinical data without actual DNA samples.

Metformin Response Heritability

The study identified a significant but modest heritable component for metformin response:

  • Males: $h^2 = 15.9\%$ (95% CI: 1.2% – 30.5%)
  • Females: $h^2 = 20.9\%$ (95% CI: 7.5% – 34.3%)

Results remained consistent after adjusting for pre-treatment HbA1c% in females and when analyzing proportional rather than absolute reduction in HbA1c%. The average absolute reduction in HbA1c% was 0.86%, consistent with clinical expectations. By using a cohort of nearly 75,000 patients, the researchers achieved greater statistical power and tighter confidence intervals than previous genetic-based studies.

Discussion

This research represents the first estimation of drug response heritability using EHR data. The findings suggest that while genetics play a role, approximately 80% of the variation in metformin response is driven by non-genetic factors, such as the gut microbiome, lifestyle, and medication adherence.

The study highlights the potential of EHRs as a powerful resource for biological research. By leveraging population-scale pedigrees, researchers can extract deep biological insights from "noisy" clinical data. Future work should focus on integrating family medical history into clinical prediction tools to help clinicians identify patients who may require earlier transition to second-line treatments.

Summary updated

Abstract

<title>Abstract</title> Variability of response to medication is a well known phenomenon, determined by both environmental and genetic factors. Understanding the heritable component of the response to medication is of great interest but challenging due to several reasons, including small study cohorts and computational limitations. Here, we studied the heritability of variation in the glycaemic response to metformin, first-line therapeutic agent for type 2 diabetes (T2D), by leveraging 17 years of electronic health records (EHR) data from Israel’s largest healthcare service provider, consisting of over five million patients of diverse ethnicities and socio-economic background. Our cohort consisted of 74,871 T2D patients treated with metformin, with an accumulated number of 1,358,776 HbA1C measurements and 323,260 metformin prescriptions. We estimated the explained variance of glycated hemoglobin (HbA1c%) reduction due to heritability by constructing a six-generation population-size pedigree from national registries and linking it to medical health records. Using Linear Mixed Model-based framework, a common-practice method for heritability estimation, we calculated a heritability measure of h2 = 15.9% (95% CI, 1.2% − 30.5%) for absolute reduction of HbA1c% after metformin treatment in males and h2 = 20.9% (95% CI, 7.5% − 34.3%) in females. Results remained unchanged after adjusting for pre-treatment HbA1c% in females, and for both genders in proportional reduction of HbA1c%. To the best of our knowledge, our work is the first to estimate heritability of drug response using EHR data. We demonstrated that while response to metformin treatment has a heritable component, most of the variation is likely due to other factors, further motivating non-genetic analyses aimed at unraveling metformin’s mechanism of action.
BibTeX
@inproceedings{kalka2021estimating,
  author = {Iris Kalka and Amir Gavrieli and Smadar Shilo and Hagai Rossman and Nitzan Shalom Artzi and Eran Segal},
  title = {{Estimating Heritability of Glycaemic Response to Metformin using Nationwide Electronic Health Records andPopulation-Sized Pedigree}},
  booktitle = {Research Square},
  year = {2021},
  doi = {10.21203/rs.3.rs-122793/v1},
}
Figure